Original Research
Accepted on 30 Jul 2025
Ruxolitinib and decitabine plus a busulfan-cyclophosphamide conditioning regimen for relapse prophylaxis in patients with high-risk acute myeloid leukemia or myelodysplastic syndromes
in Alloimmunity and Transplantation